{"DataElement":{"publicId":"3098985","version":"1","preferredName":"Biological Therapy Plan Type","preferredDefinition":"the type as related to planned biological therapy (a form of treatment that implies the administration of substances which produce a biological reaction in the organism enhancing or restoring the host immune response, modifying the behavior of cancer cells, blocking the pathways of cell neoplastic transformation and tumor ability to metastasize, or facilitating the repairment of cells damaged by aggressive forms of cancer treatment).","longName":"3091352v1.0:3098982v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3091352","version":"1","preferredName":"Biological Therapy Plan","preferredDefinition":"information related to planned biological therapy (a form of treatment that implies the administration of substances which produce a biological reaction in the organism enhancing or restoring the host immune response, modifying the behavior of cancer cells, blocking the pathways of cell neoplastic transformation and tumor ability to metastasize, or facilitating the repairment of cells damaged by aggressive forms of cancer treatment).","longName":"3091350v1.0:2475238v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"3091350","version":"1","preferredName":"Biological Therapy","preferredDefinition":"Biological therapy is a form of treatment that implies the administration of substances which produce a biological reaction in the organism enhancing or restoring the host immune response, modifying the behavior of cancer cells, blocking the pathways of cell neoplastic transformation and tumor ability to metastasize, or facilitating the repairment of cells damaged by aggressive forms of cancer treatment.  It includes the use of sera, antitoxins, vaccines, genes, cells, tissues, and organs","longName":"C15187","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biological Therapy","conceptCode":"C15187","definition":"A type of treatment that uses substances derived from or made by living organisms to treat disease; this includes both naturally occurring and synthetic products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"871FD799-7506-5192-E040-BB89AD4362C8","latestVersionIndicator":"Yes","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"ONEDATA","dateModified":"2010-05-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2475238","version":"1","preferredName":"Planned","preferredDefinition":"Planned; devised, contrived, or formed in design.","longName":"C25619","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11A2D427-7660-5E1B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-17","modifiedBy":"ONEDATA","dateModified":"2006-04-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"871FD799-7514-5192-E040-BB89AD4362C8","latestVersionIndicator":"Yes","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3098982","version":"1","preferredName":"Biologic Therapy Plan Type","preferredDefinition":"a subdivision of biologic therapy being planned.","longName":"3098982v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No biologic therapy","valueDescription":"No biologic therapy","ValueMeaning":{"publicId":"3098983","version":"1","preferredName":"No biologic therapy","longName":"3098983","preferredDefinition":"No biologic therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8763F26E-43BF-BA80-E040-BB89AD430D22","latestVersionIndicator":"Yes","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8763F26E-43D8-BA80-E040-BB89AD430D22","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"ONEDATA","dateModified":"2010-05-24","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"2574306","version":"1","preferredName":"Bevacizumab","longName":"2574306","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF4F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"ALAIS","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8763F26E-43E2-BA80-E040-BB89AD430D22","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"ONEDATA","dateModified":"2010-05-24","deletedIndicator":"No"},{"value":"Cetuximab","valueDescription":"Cetuximab","ValueMeaning":{"publicId":"2574309","version":"1","preferredName":"Cetuximab","longName":"2574309","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8763F26E-43EC-BA80-E040-BB89AD430D22","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"ONEDATA","dateModified":"2010-05-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8763F26E-43A9-BA80-E040-BB89AD430D22","latestVersionIndicator":"Yes","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"ALAIS","dateModified":"2010-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Planned biologic therapy","type":"Preferred Question Text","description":"Planned biologic therapy","url":null,"context":"CTEP"}],"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8763F26E-43F6-BA80-E040-BB89AD430D22","latestVersionIndicator":"Yes","beginDate":"2010-05-24","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-24","modifiedBy":"ALAIS","dateModified":"2010-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}